Abstract
The effect of the angiotensin II receptor blocker, candesartan cilexetil, on proteinuria was examined in a prospective, multicenter, randomized, double-blind study in Japanese subjects with type 2 diabetes. This study enrolled diabetic subjects with confirmed proteinuria into four groups for 12 weeks of treatment with placebo or candesartan cilexetil 2, 4, or 8 mg. The contribution of the angiotensin converting enzyme (ACE) gene polymorphism to the effect of candesartan cilexetil was also examined. In 127 subjects, candesartan cilexetil showed a dose-related reduction in proteinuria after 12 weeks of treatment (F = 9.45, P = 0.0013), with a 18.1% reduction in the 4-mg group, and a 5.8% reduction in the 8-mg group, in contrast to a 32.2% increase in the placebo group, and a 0.8% increase in the 2-mg group. These results indicate that candesartan cilexetil is useful in reducing proteinuria in diabetic subjects when compared with placebo. In addition, candesartan cilexetil seems to be effective in subjects with both the II and DD genotypes of the ACE gene.
References
Nov 1, 1995·The Journal of Clinical Investigation·H YoshidaO Sakai
Mar 1, 1997·Kidney International·A J ApperlooP E de Jong
Apr 29, 1998·Kidney International·P JacobsenH H Parving
Sep 3, 1998·Diabetes·G PennoJ H Fuller
Sep 11, 1998·BMJ : British Medical Journal
Dec 9, 2000·BMJ : British Medical Journal·C E MogensenM E Cooper
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Jun 26, 2002·Kidney International·Steen AndersenHans-Henrik Parving
Aug 7, 2002·Circulation·Giancarlo VibertiUNKNOWN MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators
Dec 28, 2002·Diabetes Care·Kasper RossingHans-Henrik Parving
Feb 4, 2003·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Kiyoshi KurokawaNobuya Ogawa
Apr 30, 2003·Diabetes Care·Steen AndersenHans-Henrik Parving
Citations
Apr 18, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hiroyuki ShimizuMasatomo Mori
Sep 27, 2005·BMJ : British Medical Journal·Michael A McDonaldRoss T Tsuyuki
Mar 18, 2009·Pharmacogenomics·Michael Rudnicki, Gert Mayer
Jan 28, 2010·Expert Opinion on Drug Metabolism & Toxicology·Kim TaverneOlaf Klungel
Aug 23, 2005·Diabetes/metabolism Research and Reviews
May 23, 2014·Diabetes Research and Clinical Practice·S NakataniM Inaba
Jan 15, 2015·Journal of Diabetes Research·Sung-Kyu Ha
Mar 7, 2007·Diabetes Research and Clinical Practice·José A García Donaire, Luis M Ruilope
Mar 28, 2018·Journal of Diabetes Investigation·Masakazu HanedaEiichi Araki
Aug 23, 2006·Circulation·Ross T Tsuyuki, Michael A McDonald
Sep 9, 2006·Kidney & Blood Pressure Research·Hyeong Cheon ParkDae Suk Han
Jun 14, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Piero RuggenentiGiuseppe Remuzzi
Sep 7, 2011·Journal of Preventive Medicine and Public Health = Yebang Ŭihakhoe Chi·Sayantan BiswasTarun Sharma
Apr 9, 2016·Journal of Preventive Medicine and Public Health = Yebang Ŭihakhoe Chi·Hyungseon YeomIl Suh
Dec 14, 2018·Journal of Diabetes Research·Hidenori HirukawaHideaki Kaneto
Jan 31, 2009·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Mohamad M Al KhalafSuhail A R Doi
Jan 4, 2019·Diabetology International·Masakazu HanedaEiichi Araki
Aug 18, 2020·Diabetology International·Eiichi ArakiNarihito Yoshioka
Oct 7, 2020·Journal of Diabetes Investigation·Eiichi ArakiNarihito Yoshioka